Insights

Innovative Therapeutics Xintela specializes in combining stem cell therapy and targeted cancer treatments using its proprietary integrin α10β1 marker, presenting opportunities to collaborate on advanced regenerative medicine and oncology solutions.

Clinical Development Stage With XSTEM® in clinical development for knee osteoarthritis and leg ulcers, there is potential for partnerships or sales of complementary medical devices, diagnostics, or support services to accelerate clinical trials.

Strategic Partnerships Recent collaborations with Carnegie Investment Bank and leadership appointments suggest Xintela is expanding its network, providing openings to introduce innovative funding, advisory, or research partnership opportunities.

Market Focus Focusing on aggressive cancer types such as triple-negative breast cancer and glioblastoma offers avenues for targeted therapy sales, medical device integration, or co-development with institutions involved in oncology.

Financial Position With a revenue range of 1 to 10 million dollars, Xintela presents a fertile ground for early-stage biotech solutions, clinical support services, or pilot projects that align with their upcoming product launches and ongoing trials.

Xintela AB Email Formats	Example	Percentage
First.Last@xintela.se	John.Doe@xintela.se	60%
First@xintela.se	John@xintela.se	29%
Last@xintela.se	Doe@xintela.se	11%

Xintela AB Email Formats

Example

Percentage

First.Last@xintela.se

John.Doe@xintela.se

60%

First@xintela.se

John@xintela.se

29%

Last@xintela.se

Doe@xintela.se

11%

Frequently Asked Questions

Where is Xintela AB's headquarters located?

Xintela AB's main headquarters is located at Lund, Skåne 223 81 Sweden. The company has employees across 1 continents, including Europe.

What is Xintela AB's phone number?

You can contact Xintela AB's main corporate office by phone at

+46-70-329-1****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Xintela AB's official website and social media links?

Xintela AB's official website is xintela.se and has social profiles on LinkedIn Crunchbase.

What is Xintela AB's SIC code NAICS code?

Xintela AB's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Xintela AB have currently?

As of June 2026, Xintela AB has approximately 20 employees across 1 continents, including Europe. Key team members include Ceo: E. L.Ceo: E. L.Cfo: G. T.. Explore Xintela AB's employee directory with LeadIQ.

What industry does Xintela AB belong to?

Xintela AB operates in the Biotechnology Research industry.

What technology does Xintela AB use?

Xintela AB's tech stack includes jQueryAdobe Fonts.

What is Xintela AB's email format?

Xintela AB's email format typically follows the pattern of First.Last@xintela.se. Find more Xintela AB email formats with LeadIQ.

When was Xintela AB founded?

Xintela AB was founded in 2009.

Xintela AB

Q: What is Xintela AB's official website and social media links?

Xintela AB's official website is xintela.se. Xintela AB has social profiles on LinkedIn.

Q: How many employees does Xintela AB have currently?

Xintela AB has approximately 20 employees.

Q: What technology does Xintela AB use?

Xintela AB's tech stack includes Adobe Fonts, jQuery.

Q: What is Xintela AB's NAICS code?

Xintela AB's NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).

Biotechnology ResearchSkåne, Sweden11-50 Employees

Xintela AB is a biotechnology research company based in Lund, Skåne, Sweden, with 11-50 employees. The company develops medical products in stem cell therapy and targeted cancer therapy, centered on the cell surface marker integrin α10β1 found on mesenchymal stem cells and on certain aggressive cancer cells. Its stem cell product XSTEM is selected and quality assured using integrin α10β1, produced in a GMP-approved manufacturing facility, and in clinical development for knee osteoarthritis and difficult-to-heal leg ulcers. In cancer therapy, the program is led by its wholly owned subsidiary Targinta AB, developing therapeutic antibodies targeting integrin α10β1 for triple-negative breast cancer and glioblastoma. Recent developments include the appointment of Lucienne Vonk as Chief Scientific Officer in 2024 and a 2023 partnership with Carnegie Investment Bank AB as Certified Adviser.

Insights

Similar companies to Xintela AB

Rubius Therapeutics

Vertex Pharmaceuticals

Cellectis

Editas Medicine

bluebird bio

CRISPR Therapeutics

Xintela AB Tech Stack

Media & News

Xintela AB hires Lucienne Vonk as Chief Scientific Officer.

Xintela AB partners with Carnegie Investment Bank AB.

Xintela AB hired Lars Hedbys as Board of Directors on Nov 12th '20.

Xintela AB launches PCT) patent application for quality-assured chondrocytes.

Xintela AB's Email Address Formats